Cargando…

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China

BACKGROUND: Lipid-lowering therapy (LLT) is one of the key strategies for reducing the atherosclerotic cardiovascular disease (ASCVD) burden. However, little is known about the percentage of people in need of different LLT regimens to achieve optimal targets of low-density lipoprotein cholesterol (L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bi, Lei, Yi, Jiayi, Wu, Chaoqun, Hu, Shuang, Zhang, Xingyi, Lu, Jiapeng, Liu, Jiamin, Zhang, Haibo, Yang, Yang, Cui, Jianlan, Xu, Wei, Song, Lijuan, Guo, Yuanlin, Li, Xi, Zheng, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996051/ https://www.ncbi.nlm.nih.gov/pubmed/35419429 http://dx.doi.org/10.3389/fcvm.2022.839571

Ejemplares similares

Development and validation of a risk prediction model for in-hospital major cardiovascular events in patients hospitalised for acute myocardial infarction
por: Wu, Chaoqun, et al.
Publicado: (2021)

Prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in China
por: Wang, Bin, et al.
Publicado: (2022)

Healthy lifestyle behaviours and all-cause and cardiovascular mortality among 0.9 million Chinese adults
por: Zhang, Xingyi, et al.
Publicado: (2021)

Association Between Weight Gain From Young to Middle Adulthood and Metabolic Syndrome Across Different BMI Categories at Young Adulthood
por: Wang, Xiuling, et al.
Publicado: (2022)

Effects of intensive lipid lowering compared with moderate-intensity lipid lowering on coronary atherosclerotic plaque phenotype and major adverse cardiovascular events in adults with low to intermediate 10-year ASCVD risk (ILLUMINATION study): protocol for a multicentre, open-label, blinded-endpoint, randomised controlled trial
por: Zheng, Jianan, et al.
Publicado: (2023)

Paeonol for the Treatment of Atherosclerotic Cardiovascular Disease: A Pharmacological and Mechanistic Overview
por: Wu, Min, et al.
Publicado: (2021)

Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment
por: Wang, Kexin, et al.
Publicado: (2022)

The Spectrum of B Cell Functions in Atherosclerotic Cardiovascular Disease
por: Smeets, Diede, et al.
Publicado: (2022)

Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis
por: Han, Xue, et al.
Publicado: (2022)

Association of Advanced Glycation End Products With Lower-Extremity Atherosclerotic Disease in Type 2 Diabetes Mellitus
por: Ying, Lingwen, et al.
Publicado: (2021)

Predictive value of 10-year atherosclerotic cardiovascular disease risk equations from the China-PAR for new-onset lower extremity peripheral artery disease
por: He, Pengkang, et al.
Publicado: (2022)

Lipid‐lowering treatment patterns in patients with new cardiovascular events – estimates from population‐based register data in Sweden
por: Hallberg, S., et al.
Publicado: (2016)

Association Between Periodontal Disease and Atherosclerotic Cardiovascular Diseases: Revisited
por: Zardawi, Faraedon, et al.
Publicado: (2021)

Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the heart of the issue
por: Gabbiadini, Roberto, et al.
Publicado: (2023)

Gender Differences in Atherosclerotic Vascular Disease: From Lipids to Clinical Outcomes
por: Vakhtangadze, Tamar, et al.
Publicado: (2021)

Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study
por: Guan, Xu-Min, et al.
Publicado: (2023)

E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease
por: Poels, Kikkie, et al.
Publicado: (2020)

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
por: Finney, Alexandra C., et al.
Publicado: (2023)

Common variable immunodeficiency—an independent risk factor for atherosclerotic cardiovascular diseases
por: Mattila, Juho, et al.
Publicado: (2023)

Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases
por: Choi, Su-Yeon, et al.
Publicado: (2020)

Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care – a retrospective database study
por: Jameson, K, et al.
Publicado: (2013)

Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
por: Dehghanbanadaki, Hojat, et al.
Publicado: (2023)

Alcohol use disorder and its association with quality of life and mortality in Chinese male adults: a population-based cohort study
por: Lu, Jiapeng, et al.
Publicado: (2022)

Educational inequalities in mortality and their mediators among generations across four decades: nationwide, population based, prospective cohort study based on the ChinaHEART project
por: Lu, Jiapeng, et al.
Publicado: (2023)

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
por: Journath, Gunilla, et al.
Publicado: (2017)

Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
por: Desai, Nihar R., et al.
Publicado: (2022)

Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
por: Faridi, Kamil F., et al.
Publicado: (2023)

The Associations of Lipid Profiles With Cardiovascular Diseases and Death in a 10-Year Prospective Cohort Study
por: Dong, Jiayi, et al.
Publicado: (2021)

Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor
por: Nahmias, Avital, et al.
Publicado: (2020)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023)

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
por: Matta, Anthony, et al.
Publicado: (2023)

The relationship between atherosclerotic disease and relapse during ATD treatment
por: Zhu, Xinxin, et al.
Publicado: (2022)

The relationship between Type D personality with atherosclerotic plaque and cardiovascular events: The mediation effect of inflammation and kynurenine/tryptophan metabolism
por: Wang, Yini, et al.
Publicado: (2022)

Differentially Expressed Circular Non-coding RNAs in Atherosclerotic Aortic Vessels and Their Potential Functions in Endothelial Injury
por: Li, Houwei, et al.
Publicado: (2021)

The effect of telemedicine on secondary prevention of atherosclerotic cardiovascular disease: A systematic review and meta-analysis
por: Deng, Liangying, et al.
Publicado: (2022)

Proteotoxic stress response in atherosclerotic cardiovascular disease: Emerging role of heat shock factor 1
por: Ghai, Shruti, et al.
Publicado: (2023)

DNA methylation changes underlie the long-term association between periodontitis and atherosclerotic cardiovascular disease
por: Omar, Mohamed, et al.
Publicado: (2023)

Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study
por: Yang, Quanhe, et al.
Publicado: (2017)

Comprehensive Analysis of the Immune Infiltrates and Aberrant Pathways Activation in Atherosclerotic Plaque
por: Han, Hukui, et al.
Publicado: (2021)

Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK
por: Danese, Mark, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ee9sfmtvl2jogokf5f5ng84p6o